Your browser is no longer supported. Please, upgrade your browser.
QGEN QIAGEN N.V. daily Stock Chart
Index- P/E105.24 EPS (ttm)0.33 Insider Own3.60% Shs Outstand227.63M Perf Week-1.48%
Market Cap7.86B Forward P/E25.59 EPS next Y1.35 Insider Trans0.00% Shs Float225.22M Perf Month7.84%
Income76.10M PEG7.65 EPS next Q0.32 Inst Own73.80% Short Float1.64% Perf Quarter1.35%
Sales1.36B P/S5.77 EPS this Y-38.30% Inst Trans1.53% Short Ratio3.26 Perf Half Y22.72%
Book/sh10.99 P/B3.14 EPS next Y11.76% ROA1.80% Target Price34.13 Perf Year33.38%
Cash/sh2.67 P/C12.91 EPS next 5Y13.77% ROE3.00% 52W Range23.88 - 36.34 Perf YTD23.53%
Dividend- P/FCF26.81 EPS past 5Y-3.50% ROI3.30% 52W High-5.01% Beta1.13
Dividend %- Quick Ratio3.30 Sales past 5Y2.70% Gross Margin64.80% 52W Low44.58% ATR0.82
Employees4600 Current Ratio3.90 Sales Q/Q4.40% Oper. Margin6.50% RSI (14)62.51 Volatility3.97% 2.22%
OptionableYes Debt/Eq0.00 EPS Q/Q-32.70% Profit Margin5.60% Rel Volume1.48 Prev Close34.65
ShortableYes LT Debt/Eq0.55 EarningsNov 02 Payout0.00% Avg Volume1.13M Price34.52
Recom2.70 SMA204.98% SMA507.17% SMA20010.79% Volume1,675,583 Change-0.38%
Nov-03-16Upgrade BofA/Merrill Underperform → Neutral
Aug-01-16Upgrade HSBC Securities Hold → Buy
Aug-01-16Reiterated Mizuho Neutral $22 → $25
Feb-03-16Reiterated Barclays Overweight $28 → $27
Nov-12-15Initiated Stifel Hold
Sep-15-15Initiated Morgan Stanley Overweight $33
Jul-30-15Reiterated Mizuho Neutral $23 → $25
Jul-30-15Reiterated Barclays Overweight $27 → $31
Mar-10-15Initiated UBS Buy $28
Jan-07-15Upgrade Barclays Equal Weight → Overweight $24 → $28
Oct-30-14Reiterated Mizuho Neutral $21 → $23
May-01-13Downgrade Barclays Overweight → Equal Weight $21 → $19
Apr-30-13Reiterated ISI Group Neutral $22.50 → $21
Jan-30-13Reiterated Mizuho Neutral $17 → $19
Jan-28-13Reiterated Barclays Overweight $18 → $21
Oct-11-12Downgrade HSBC Securities Neutral → Underweight
Apr-26-12Reiterated Mizuho Neutral $15 → $17
Oct-17-11Reiterated Barclays Capital Overweight $21 → $15
Jul-25-11Downgrade Wedbush Outperform → Neutral $24 → $19
Apr-13-11Initiated HSBC Securities Neutral
Oct-16-17 06:20AM  QIAGEN N.V. to Report Third Quarter and First Nine Months of 2017 Results PR Newswire
Oct-13-17 09:41AM  Henry Schein Gains on Strategic Buyouts, Cost Concern a Woe Zacks
09:03AM  NuVasive's (NUVA) PRECICE System Gets Expanded FDA Approval Zacks
08:42AM  Abbott Banks on FDA Approvals and Buyouts, Competition Rife Zacks
08:41AM  Bruker (BRKR) at a 52-Week High: What's Driving the Stock? Zacks
Oct-12-17 04:05PM  QIAGEN Bioinformatics and NGS Solutions Enable Genomic Breakthroughs PR Newswire
09:34AM  LabCorp (LH) Strong on Strategic Planning, Competition Rife Zacks
08:48AM  Henry Schein Closes Merritt Buyout, Expands in Animal Health Zacks
08:47AM  CryoLife to Buy JOTEC, Preliminary Revenue Result Out for Q3 Zacks
Oct-11-17 09:55AM  QIAGEN Banks on Tie-Ups & Product Launches, Competition Rife Zacks
03:00AM  Qiagen Trying To Close In On Key Technical Benchmark Investor's Business Daily
Oct-10-17 09:34AM  QIAGEN Partners With CENTOGENE, Boosts Bioinformatics Suite Zacks
03:00AM  Qiagen Trying To Close In On Key Technical Benchmark Investor's Business Daily
Oct-09-17 04:05PM  QIAGEN and CENTOGENE to Collaborate in Bioinformatics for Genetic Diseases PR Newswire
11:58AM  ETFs with exposure to QIAGEN NV : October 9, 2017 Capital Cube
Oct-06-17 09:33AM  QIAGEN's QFT-Plus Launch to Boost Molecular Diagnostics Arm Zacks
09:04AM  QIAGEN NV :QGEN-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 Capital Cube
Oct-05-17 04:05PM  QIAGEN Launches Fourth-generation QuantiFERON®-TB Gold Plus in the U.S. PR Newswire
Oct-02-17 04:05PM  QIAGEN Achieves ISO Certification for State-of-the-art Quality in Forensics PR Newswire
Sep-26-17 08:12AM  QIAGEN NV breached its 50 day moving average in a Bullish Manner : QGEN-US : September 26, 2017 Capital Cube
Sep-12-17 08:02AM  See what the IHS Markit Score report has to say about Qiagen NV. Markit
Aug-21-17 04:10PM  QIAGEN and Clinical Genomics partner on liquid biopsies to monitor patients for recurrence of colorectal cancer GlobeNewswire
04:05PM  QIAGEN and Clinical Genomics Partner on Liquid Biopsies to Monitor Patients for Recurrence of Colorectal Cancer PR Newswire
Aug-17-17 08:07AM  See what the IHS Markit Score report has to say about Qiagen NV. Markit
Aug-14-17 06:08PM  QIAGEN NV Value Analysis (NASDAQ:QGEN) : August 14, 2017 Capital Cube
Aug-12-17 02:51AM  Edited Transcript of QGEN earnings conference call or presentation 28-Jul-17 1:00pm GMT Thomson Reuters StreetEvents
Aug-11-17 08:01AM  See what the IHS Markit Score report has to say about Qiagen NV. Markit
Aug-10-17 08:01AM  See what the IHS Markit Score report has to say about Qiagen NV. Markit
Jul-31-17 12:49PM  A Beat From Qiagen NV, but Only Half a Raise Motley Fool
10:03AM  QIAGEN NV breached its 50 day moving average in a Bearish Manner : QGEN-US : July 31, 2017 Capital Cube
Jul-28-17 09:46AM  QIAGEN (QGEN) Beats on Earnings & Sales in Q2, Raises View Zacks
Jul-27-17 05:46PM  Qiagen beats Street 2Q forecasts Associated Press
11:16AM  QIAGEN Reports Results for Second Quarter and First Half of 2017 PR Newswire
09:00AM  HTG Molecular Diagnostics Announces Second Companion Diagnostic Development Project with QIAGEN GlobeNewswire
Jul-13-17 04:02AM  QIAGEN N.V. to Report Second Quarter and First Half of 2017 Results PR Newswire
Jul-07-17 09:43AM  QIAGEN NV breached its 50 day moving average in a Bearish Manner : QGEN-US : July 7, 2017 Capital Cube
Jul-05-17 01:07PM  ETFs with exposure to QIAGEN NV : July 5, 2017 Capital Cube
Jun-22-17 04:18PM  ETFs with exposure to QIAGEN NV : June 22, 2017 Capital Cube
08:04AM  French health system approves reimbursement of QIAGEN's QuantiFERON latent TB test PR Newswire
Jun-16-17 12:01PM  QIAGEN NV :QGEN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Capital Cube
Jun-08-17 09:00AM  QIAGEN's QuantiFERON®-TB Gold Plus gains U.S. FDA approval PR Newswire
Jun-06-17 07:28AM  QIAGEN Strengthens Cancer Research Foothold on New License Zacks
02:00AM  QIAGEN receives U.S. FDA approval for cytomegalovirus (CMV) testing on automated QIAsymphony platform PR Newswire
Jun-05-17 10:28AM  QIAGEN & Bristol-Myers Squibb Partner on Cancer Research Zacks
Jun-03-17 01:00PM  QIAGEN expands biomarker content portfolio to support greater use of molecular diagnostics for immuno-oncology therapies PR Newswire
01:00PM  Bristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies Business Wire
May-31-17 04:42PM  3 Top Gene-Sequencing Stocks Poised for Solid Growth Motley Fool
May-11-17 08:46PM  Edited Transcript of QGEN earnings conference call or presentation 3-May-17 1:00pm GMT Thomson Reuters StreetEvents
08:15AM  Blog Coverage: INC Research Holdings Acquires Privately Held inVentiv Health Accesswire
May-08-17 09:47AM  Qiagen Banks on Molecular Diagnostic amid Currency Woes Zacks
May-04-17 02:40PM  QIAGEN NV's Getting It Done Motley Fool
May-03-17 09:40AM  QIAGEN (QGEN) Beats Q1 Earnings Estimates, Retains View Zacks
May-02-17 07:07PM  Qiagen beats Street 1Q forecasts Associated Press
04:05PM  QIAGEN Reports Results for First Quarter 2017 PR Newswire
02:00AM  QIAGEN Partners With Maccura to Localize and Commercialize GeneReader NGS System in China PR Newswire
Apr-26-17 04:30PM  QIAGEN NV Value Analysis (NASDAQ:QGEN) : April 26, 2017 Capital Cube
Apr-25-17 09:03AM  QIAGEN NV breached its 50 day moving average in a Bullish Manner : QGEN-US : April 25, 2017 Capital Cube
Apr-20-17 04:20PM  The Top Gene-Sequencing Stock to Buy in 2017 Motley Fool
Apr-12-17 04:05PM  New Research Suggests Potential for Additional Clinical Utility of QIAGEN's QuantiFERON-TB Gold Plus PR Newswire
07:00AM  Qiagen (QGEN) Down 2.6% Since Earnings Report: Can It Rebound? Zacks
Apr-06-17 12:15PM  QIAGEN Posts 2016 Annual Report on its Website PR Newswire
09:15AM  QIAGEN N.V. to Report First Quarter 2017 Results PR Newswire
Apr-04-17 11:12AM  QIAGEN Releases Favorable GeneReader Results, Expands in NGS Zacks
Apr-03-17 02:00AM  QIAGEN's GeneReader NGS System Gains Further Validation in Oncology Research Applications With New Independent Performance Review Data PR Newswire
Mar-31-17 04:05PM  QIAGEN Expands Liquid Biopsy Pipeline with AR-V7 Test in Prostate Cancer PR Newswire
Mar-30-17 04:05PM  QIAGEN Joins CANCER-ID Consortium for Liquid Biopsy Workflows PR Newswire
08:49AM  QIAGEN Offers JAK2 Kit in US, Grows in Molecular Diagnostics Zacks
08:49AM  QIAGEN Offers JAK2 Kit in US, Grows in Molecular Diagnostics at Investopedia
Mar-29-17 04:05PM  QIAGEN Launches First FDA-cleared JAK2 Test for Certain Type of Leukemia PR Newswire
Mar-28-17 08:09AM  QIAGEN NV breached its 50 day moving average in a Bullish Manner : QGEN-US : March 28, 2017 Capital Cube
Mar-09-17 01:04PM  QIAGEN NV Financials
Mar-06-17 07:54AM  QIAGEN NV breached its 50 day moving average in a Bullish Manner : QGEN-US : March 6, 2017
Feb-16-17 02:20AM  New Study Published in Lancet Respiratory Medicine Highlights QIAGEN's QuantiFERON-TB Potential to Predict Active Tuberculosis Risk in Infants PR Newswire
Feb-08-17 11:31AM  QIAGEN NV :QGEN-US: Earnings Analysis: 2016 By the Numbers : February 8, 2017 Capital Cube
Feb-06-17 11:51AM  QIAGEN NV :QGEN-US: Earnings Analysis: Q4, 2016 By the Numbers : February 6, 2017
Feb-03-17 07:23AM  QIAGEN (QGEN) Earnings Meet, Sales Miss Estimates in Q4
Feb-02-17 05:29PM  Edited Transcript of QGEN earnings conference call or presentation 2-Feb-17 2:00pm GMT
04:16PM  QIAGEN NV Continues Its Turnaround at Motley Fool
Feb-01-17 06:18PM  Qiagen meets 4Q profit forecasts
04:05PM  QIAGEN Reports Results for Fourth Quarter and Full-year 2016 PR Newswire
07:36AM  QIAGEN NV breached its 50 day moving average in a Bullish Manner : QGEN-US : February 1, 2017
07:07AM  Q4 2016 Qiagen NV Earnings Release - 4:00 pm ET
Jan-30-17 04:05PM  QIAGEN Hereditary and Rare Disease Solution Chosen by Genomics England PR Newswire
Jan-26-17 04:05PM  QIAGEN's QuantiFERON-TB Test Wins Tender for Testing of Republic of Korea Armed Forces Recruits PR Newswire
02:09AM  QIAGEN Announces Adjustment of Conversion Ratio Under its 0.375% Senior Unsecured Convertible Notes due 2019 (ISIN XS1046477235) PR Newswire
Jan-19-17 10:58PM  Better Buy: Opko Health, Inc. vs. Qiagen at Motley Fool
11:16AM  QIAGEN NV Value Analysis (NASDAQ:QGEN) : January 19, 2017
Jan-18-17 04:05PM  QIAGEN Announces Details for Completion of Approximately $250 Million Synthetic Share Repurchase PR Newswire
09:52AM  QIAGEN NV breached its 50 day moving average in a Bearish Manner : QGEN-US : January 18, 2017
06:19AM  QIAGEN N.V. to Report Fourth Quarter and Full Year of 2016 Results PR Newswire
Jan-10-17 09:00AM  Singulex Enters into Collaboration with QIAGEN to Develop Companion Diagnostics PR Newswire
07:26AM  QIAGEN (QGEN) Buys OmicSoft, Expands Bioinformatics Suite
Jan-09-17 10:15AM  QIAGEN Enhances Bioinformatics Portfolio with Acquisition of OmicSoft PR Newswire
10:05AM  QIAGEN Announces Comprehensive Range of Enhancements for GeneReader NGS System PR Newswire
10:00AM  QIAGEN Submits QuantiFERON®-TB Gold Plus for U.S. Regulatory Approval PR Newswire
Dec-23-16 08:57AM  Qiagen Poised on Fundamentals, Expansion Plans on Track
Dec-14-16 11:08AM  Illumina Stock Now Worth a Lot Less? Here's What You Need to Know at Motley Fool
Dec-12-16 05:11AM  QIAGEN Welcomes New Evidence-Based Tuberculosis Testing Guidelines from U.S. Professional Societies PR Newswire
Dec-07-16 08:26AM  Qiagen NV (QGEN) Hedge Funds Are Snapping Up at Insider Monkey
Nov-16-16 08:30AM  HTG Molecular Diagnostics and QIAGEN Team Up to Advance Precision Diagnostics GlobeNewswire
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. It offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, and library preparation for sequencing applications; and assay technology solutions. The company provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. It also offers instrumentation systems for laboratories. The company's automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories; Modaplex, a multimodal automation system; QIAcube, a sample processing instrument; EZ1 Advanced XL for automated nucleic acid purification; QIAxcel for nucleic acid separation; QIAscout that enables researchers to select and isolate viable single cells; PyroMark, a detection platform that enables real-time analysis and quantification of genetic mutations and DNA methylation patterns; QIAgility, a benchtop instrument; and ESEQuant instruments that enable optical measurement for point of need molecular testing in healthcare and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a partnership with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.